8th International Congress on Drug Therapy in HIV Infection

Key Links:

By Topic:


The 8th International Congress on Drug Therapy in HIV Infection
NOVEMBER 12-16, 2006

Conference Research Highlights

TREATMENT STRATEGIES: Several new trials are comparing the safety and efficacy of newer boosted protease inhibitor (PI) regimens with the current PI favorite, lopinavir/ritonavir (Kaletra). Preliminary data from the GEMINI Study indicate that lopinavir/ritonavir and saquinavir (Invirase) + ritonavir (Norvir) are head-to-head in terms of efficacy, but saquinavir + ritonavir may pull ahead in the category of lipid changes since it appears to cause fewer lipid abnormalities. Graeme Moyle, M.D., reports.

RESCUE THERAPY: Several studies confirm the potency and durability of tipranavir in heavily treatment-experienced patients, namely due to its high genetic barrier to resistance. Although the agent is an attractive and relatively safe option for individuals in need of potent salvage antiretrovirals, preliminary toxicity and efficacy concerns preclude its use in treatment-naive individuals. Mark Wainberg, Ph.D., reports.

INFERTILITY & HIV: HIV-infected women seeking to live normal lives by trying to have children face an extra challenge. New research suggests that HIV infection, antiretroviral therapy or both can compromise fertility by dramatically depleting mitochondrial DNA levels in oocytes. Simon D. Portsmouth, M.B.Ch.B., reports.

HIV DRUG RESISTANCE: The presence of multidrug-resistant (MDR) HIV within a population poses significant challenges with regard to treatment and transmission. Research suggests that the prevalence of MDR virus is escalating as patients gain more exposure to multiple classes of drugs. However, new findings, based on a large Portuguese database, suggest that the incidence of MDR HIV is actually decreasing, likely due to improvements in the efficacy of HIV drugs. Simon D. Portsmouth, M.B.Ch.B., reports.

OPTIONS FOR SALVAGE THERAPY: These are exciting times in antiretroviral therapy given the recent approval of several new agents and others that are nearing approval. David Cooper provided a rundown on the latest and greatest new antiretrovirals available and how best to use these agents in treatment-experienced patients. Simon D. Portsmouth, M.B.Ch.B., reports.

HAART COMPLICATIONS: Data from a prospective study conducted in the United Kingdom add to the mounting evidence showing that testing for the presence of the HLA-B*5701 allele prior to abacavir (ABC, Ziagen) exposure can dramatically reduce the incidence of hypersensitivity reaction. Graeme Moyle, M.D., reports.

More of the latest coverage >>

Check back here for the latest coverage of critical studies and key scientific presentations, featuring in-depth analysis from our team of expert faculty:

Graeme Moyle, M.D., M.B., B.S., Dip. G.U.M. Mark Nelson, M.A., M.B.B.S., M.R.C.P. Simon D. Portsmouth, M.B.Ch.B., M.R.C.P., Dip.G.U.M., D.F.F.P. Mark Wainberg, Ph.D.

About This Conference

The Body's coverage of the 8th International Congress on Drug Therapy in HIV Infection (Glasgow 2006) will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on Glasgow 2006, please visit the conference's Web site. You may also view the conference's program online.

Funding for coverage of this conference is provided, in part, by Boehringer Ingelheim.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.